0 Items
Select Page

Oropouche Virus

Oropouche virus (OROV) is one of the most common arboviruses that infects humans in Brazil. It is estimated that since the virus was first isolated in 1955, it has infected more than half a million people. However, it is often mistakenly diagnosed as Dengue, Zika or Chikungunya virus, and therefore true levels of infection are unclear.

The Native Antigen Company offers a range of Oropouche antigens to support the development of assays to reliably detect infection.

Oropouche Virus Background

Oropouche virus (OROV) is an RNA virus, belonging to the family Bunyaviridae. Phylogenetic analysis of OROV has identified 4 virus genotypes (I, II, III, IV), which all occur in Brazil. In humans, OROV causes Oropouche fever, which is clinically characterised by a rapid-onset acute febrile illness. Oropouche fever is reported to be the second most common arboviral disease, next to Dengue fever, in the Brazilian Amazon region. Other symptoms associated with the disease are like those reported for Dengue, Zika, chikungunya, yellow fever and include headache, myalgia, joint pain, nausea and vomiting. In some cases, OROV can cause a form of viral meningitis.

In humans, OROV is transmitted by the biting midge, culicoides paraensis, an insect vector that lives in urban areas and is widely distributed in South America. Since the virus was first isolated in 1955, OROV has caused 30 large-scale epidemics in the Amazon region, infecting at least 500,000 people. The incidence of Oropouche fever has now become widespread in Latin American countries where c. paraensis is present.

Considering the geographical spread of OROV and the similarity of symptoms between Oropouche and fever infections caused by Dengue, Zika, Chikungunya and Yellow Fever viruses, it is important to reliably differentiate between these arboviral diseases with accurate diagnostics.

References

  1. World Health Organization (WHO). Oropouche Virus disease – Peru. http://www.who.int/csr/don/03-june-2016-oropouche-peru/en/
  2. Vasconcelos, H.B. et al (2011). Molecular epidemiology of Oropouche virus, Brazil. Emerg Infect Dis. 17:800-6
  3. Sakkas, H. et al (2018) Oropouche Fever: A Review Viruses 10:175

Oropouche Antigens

In support of Oropouche infection research, we offer a range of antigens relevant to immunoassay and vaccine research. These include OROV Gc and Gn glycoprotiens, expressed in our mammalian cell system and the non-glycosylated nucleoprotein, expressed in E. coli.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 13 =

Live Customer Feedback